Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CRNX logo CRNX
Upturn stock ratingUpturn stock rating
CRNX logo

Crinetics Pharmaceuticals Inc (CRNX)

Upturn stock ratingUpturn stock rating
$28.76
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CRNX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

17 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Year Target Price $72.67

Year Target Price $72.67

Analyst’s Price TargetsFor last 52 week
$72.67Target price
Low$24.1
Current$28.76
high$62.53

Analysis of Past Performance

Type Stock
Historic Profit 39.91%
Avg. Invested days 53
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 2.81B USD
Price to earnings Ratio -
1Y Target Price 72.67
Price to earnings Ratio -
1Y Target Price 72.67
Volume (30-day avg) 17
Beta 0.28
52 Weeks Range 24.10 - 62.53
Updated Date 06/29/2025
52 Weeks Range 24.10 - 62.53
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.8

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -30860.11%

Management Effectiveness

Return on Assets (TTM) -20.13%
Return on Equity (TTM) -30.84%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1590846105
Price to Sales(TTM) 3692.97
Enterprise Value 1590846105
Price to Sales(TTM) 3692.97
Enterprise Value to Revenue 2093.22
Enterprise Value to EBITDA -13.4
Shares Outstanding 93680096
Shares Floating 92278675
Shares Outstanding 93680096
Shares Floating 92278675
Percent Insiders 2.03
Percent Institutions 112.42

Analyst Ratings

Rating 4
Target Price 72.67
Buy 5
Strong Buy 11
Buy 5
Strong Buy 11
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Crinetics Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Crinetics Pharmaceuticals Inc. is a biopharmaceutical company founded in 2008. It focuses on developing novel therapeutics for endocrine diseases and endocrine-related tumors. It went public in 2018. The company has evolved from early research to clinical-stage development, targeting unmet needs in endocrinology.

business area logo Core Business Areas

  • Drug Development: Focused on creating oral, non-peptide therapeutics for rare endocrine disorders and endocrine-related tumors.
  • Clinical Trials: Conducting Phase 1, 2, and 3 clinical trials for various drug candidates.
  • Research and Discovery: Engaged in ongoing research to identify and develop new therapeutic targets and drug candidates.

leadership logo Leadership and Structure

The company is led by CEO Scott Struthers. The organizational structure includes research and development, clinical operations, and commercial teams.

Top Products and Market Share

overview logo Key Offerings

  • Paltusotine: Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 (SST2) agonist, is Crinetics's leading drug candidate currently in phase III trials for acromegaly. The market share is currently zero because it is not yet FDA approved. Competitors include Novartis (Sandostatin, Pasireotide).
  • CRN04894: CRN04894, is an oral ACTH antagonist is in phase II clinical trials for congenital adrenal hyperplasia (CAH). Market share is currently zero, awaiting FDA approval. Competitors include generic hydrocortisone, and newer options from Neurocrine Biosciences.
  • CRN04777: CRN04777 is an oral selective nonpeptide somatostatin receptor type 5 (SST5) agonist, is in phase I trials for hyperinsulinism. Market share is currently zero because it is not yet FDA approved. Competitors include diazoxide and surgery.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The endocrine market focuses on hormonal imbalances and related diseases.

Positioning

Crinetics is positioned as a specialized biopharmaceutical company focused on oral, non-peptide therapeutics for endocrine diseases, distinguishing it from companies focusing on injectable therapies.

Total Addressable Market (TAM)

The TAM for endocrine therapies is estimated at billions of dollars annually. Crinetics is targeting specific niches within this large market, particularly rare endocrine disorders, allowing for potentially significant market penetration. Acromegaly market is around $750M, CAH $2.3 Billion

Upturn SWOT Analysis

Strengths

  • Novel oral drug candidates
  • Strong intellectual property portfolio
  • Experienced management team
  • Focus on underserved endocrine markets

Weaknesses

  • Dependence on clinical trial success
  • Limited commercial infrastructure
  • High cash burn rate
  • Competition from established players

Opportunities

  • Successful clinical trial results leading to FDA approval
  • Expansion into new endocrine indications
  • Strategic partnerships with larger pharmaceutical companies
  • Acquisition by a larger pharmaceutical company

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from other companies developing similar therapies
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • NVS
  • SNY
  • TEVA
  • NBIX

Competitive Landscape

Crinetics has an advantage by developing oral versions of drugs that were previously only available by injection, but it still faces significant competition from larger companies with established products and commercial infrastructure.

Growth Trajectory and Initiatives

Historical Growth: Historically, Crinetics has experienced growth in its pipeline and has secured funding through public offerings and collaborations.

Future Projections: Future growth is contingent on successful clinical trials and FDA approvals. Analyst estimates vary, but generally project significant revenue growth if paltusotine is approved.

Recent Initiatives: Recent initiatives include the advancement of paltusotine into Phase 3 trials and the development of new drug candidates for other endocrine disorders.

Summary

Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company with potential in the oral endocrine therapeutics market. Success hinges heavily on the outcomes of its ongoing clinical trials, particularly paltusotine. While it has a strong IP portfolio and is tackling underserved markets, it faces risks associated with clinical development and competition. Future success requires favorable trial data and successful navigation of regulatory hurdles.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Crinetics Pharmaceuticals Inc. Investor Relations
  • SEC Filings
  • Analyst Reports
  • ClinicalTrials.gov

Disclaimers:

The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may not be precise. Investing in biopharmaceutical companies involves significant risks.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Crinetics Pharmaceuticals Inc

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2018-07-18
Founder, President, CEO & Director Dr. R. Scott Struthers Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 437
Full time employees 437

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.